RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cardiol Therapeutics Stock

Cardiol Therapeutics Net Income 2025

Cardiol Therapeutics Net Income

-37.59 M CAD

Ticker

CRDL.TO

ISIN

CA14161Y2006

WKN

A2PA9E

In 2025, Cardiol Therapeutics's profit amounted to -37.59 M CAD, a 2.5% increase from the -36.68 M CAD profit recorded in the previous year.

The Cardiol Therapeutics Net Income history

YEARNET INCOME (undefined CAD)
2030e166.08
2029e70.97
2028e29.27
2027e-13.36
2026e-54.75
2025e-37.59
2024-36.68
2023-28.13
2022-30.93
2021-31.64
2020-20.64
2019-13.68
2018-15.89
2017-1.66

Cardiol Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cardiol Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cardiol Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cardiol Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cardiol Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cardiol Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cardiol Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cardiol Therapeutics’s growth potential.

Cardiol Therapeutics Revenue, EBIT and net profit per share

DateCardiol Therapeutics RevenueCardiol Therapeutics EBITCardiol Therapeutics Net Income
2030e336.37 M undefined0 undefined166.08 M undefined
2029e202.15 M undefined143.13 M undefined70.97 M undefined
2028e125.2 M undefined70.35 M undefined29.27 M undefined
2027e18.82 M undefined-13.41 M undefined-13.36 M undefined
2026e2.3 M undefined-34.22 M undefined-54.75 M undefined
2025e0 undefined-37.84 M undefined-37.59 M undefined
20240 undefined-40.28 M undefined-36.68 M undefined
20230 undefined-29.79 M undefined-28.13 M undefined
20220 undefined-41.34 M undefined-30.93 M undefined
202180,000 undefined-38.66 M undefined-31.64 M undefined
20200 undefined-20.69 M undefined-20.64 M undefined
20190 undefined-14.13 M undefined-13.68 M undefined
20180 undefined-7.1 M undefined-15.89 M undefined
20170 undefined-1.6 M undefined-1.66 M undefined

Cardiol Therapeutics stock margins

The Cardiol Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cardiol Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cardiol Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cardiol Therapeutics's sales revenue. A higher gross margin percentage indicates that the Cardiol Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cardiol Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cardiol Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cardiol Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cardiol Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cardiol Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cardiol Therapeutics Margin History

Cardiol Therapeutics Gross marginCardiol Therapeutics Profit marginCardiol Therapeutics EBIT marginCardiol Therapeutics Profit margin
2030e98.75 %0 %49.37 %
2029e98.75 %70.8 %35.11 %
2028e98.75 %56.19 %23.37 %
2027e98.75 %-71.26 %-70.97 %
2026e98.75 %-1,487.87 %-2,380.41 %
2025e98.75 %0 %0 %
202498.75 %0 %0 %
202398.75 %0 %0 %
202298.75 %0 %0 %
202198.75 %-48,325 %-39,550 %
202098.75 %0 %0 %
201998.75 %0 %0 %
201898.75 %0 %0 %
201798.75 %0 %0 %

Cardiol Therapeutics Aktienanalyse

What does Cardiol Therapeutics do?

Cardiol Therapeutics Inc is an international biopharmaceutical company specializing in the development of innovative therapies for the treatment of heart diseases. The company was founded in 2006 in Canada and has since built a broad portfolio of products and technologies to improve the treatment of heart diseases. The company's business model is based on research and development of innovative therapies that aim to provide patients with more effective treatments for heart diseases. They collaborate closely with renowned research institutions and clinics worldwide to develop a wide range of innovative treatment options. The company has also specialized in the study of cannabinoids for the treatment of heart diseases, focusing on the development of medications tailored to the needs of patients with heart diseases. They have developed CardiolRx, a patented technology based on cannabinoids, which has shown promising results in clinical studies for the treatment of severe heart diseases such as heart failure and myocarditis. Overall, Cardiol Therapeutics Inc is a biopharmaceutical company dedicated to developing therapies for the treatment of heart diseases, with a focus on collaboration, innovative products, and the potential to significantly improve patient care. Cardiol Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Cardiol Therapeutics's Profit Margins

The profit margins of Cardiol Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cardiol Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Cardiol Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Cardiol Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Cardiol Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Cardiol Therapeutics stock

How much profit has Cardiol Therapeutics made this year?

Cardiol Therapeutics has made -37.59 M CAD this year.

How has the profit developed compared to last year?

The profit has increased by 2.5% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Cardiol Therapeutics publish its earnings?

Cardiol Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Cardiol Therapeutics?

The profits of Cardiol Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Cardiol Therapeutics?

You can learn more about the earnings of Cardiol Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Cardiol Therapeutics pay?

Over the past 12 months, Cardiol Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cardiol Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Cardiol Therapeutics?

The current dividend yield of Cardiol Therapeutics is .

When does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cardiol Therapeutics?

Cardiol Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cardiol Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cardiol Therapeutics located?

Cardiol Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cardiol Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cardiol Therapeutics from 6/25/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 6/25/2025.

When did Cardiol Therapeutics pay the last dividend?

The last dividend was paid out on 6/25/2025.

What was the dividend of Cardiol Therapeutics in the year 2024?

In the year 2024, Cardiol Therapeutics distributed 0 CAD as dividends.

In which currency does Cardiol Therapeutics pay out the dividend?

The dividends of Cardiol Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cardiol Therapeutics

Our stock analysis for Cardiol Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cardiol Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.